European legislation on regenerative medicine and its implementation in Germany in the new Law on Medication are slowing down the path to innovation for patients.
The German biotechnology sector is growing. This is proved by a significantly higher turnover of €2.4 billion (+9%), record-breaking funding of €700 million (+122%), and an increased number of employees in commercial biotechnology of around 32,500 (+3%). The number of companies (538) also rose. Expenditure on research and development was around €1 billion in 2010.
The European patent was one of the topics on the agenda at the latest EuropaBio National Associations Council (NAC) conference at the beginning of April. On 13 April 2011, the European Commission presented two draft sets of regulations on organising a joint patent in terms of enhanced cooperation.
Biotechnology, pharmaceutics and medical technology cooperation trip to Beijing, Guangzhou and Shenzhen from 14 – 21 May 2011
Following the very successful biotech trip in 2010, the Federal Ministry of Economics and Technology and Germany Trade & Invest (GTAI) have asked Brücke Osteuropa (the German Association for Economic and Technological Cooperation with Eastern Europe and Asia) and BIO Deutschland (the German biotechnology industry association) to organise a second cooperation trip to China for this sector.